{"id":694454,"date":"2024-04-10T17:48:02","date_gmt":"2024-04-10T17:48:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=694454"},"modified":"2024-04-10T17:48:02","modified_gmt":"2024-04-10T17:48:02","slug":"actinic-keratosis-market-size-in-the-7mm-is-expected-to-grow-by-2032-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/actinic-keratosis-market-size-in-the-7mm-is-expected-to-grow-by-2032-delveinsight_694454.html","title":{"rendered":"Actinic Keratosis Market Size in the 7MM is Expected to Grow by 2032 | DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1712750350.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Actinic Keratosis Market Size in the 7MM is Expected to Grow by 2032 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1712750350.jpeg\" alt=\"Actinic Keratosis Market Size in the 7MM is Expected to Grow by 2032 | DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8220;<strong>Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2032<\/strong>&#8221; report delivers an in-depth understanding of the Actinic Keratosis, historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Actinic Keratosis Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The increase in Actinic Keratosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.<\/li>\n<li>As per DelveInsight analysis, the Actinic Keratosis market is anticipated to witness growth at a considerable CAGR.<\/li>\n<li>The leading Actinic Keratosis Companies working in the market include Novartis AG, GlaxoSmithKline plc., Almirall, LLC, LEO Pharma Inc., Cipher Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Biofrontera, Nestle SA, Bausch Health Companies Inc., Pierre Fabre Pharmaceuticals, Inc., and others.<\/li>\n<li>Promising Actinic Keratosis Pipeline Therapies in the various stages of development include KX01 ointment 1%, Solaraze, Diclofenac Sodium Gel, Solaraze 3% Topical Gel, PEP005 Gel, and others.<\/li>\n<li>March 2024: Infectopharm Arzneimittel GmbH announced a study of Phase 3 clinical trials for Solcera and Solaraze. The KOHDIAK study is a prospective, three-armed, randomised, double-blind study to evaluate the efficacy and safety of the treatment of mild and moderate actinic keratosis with a 5% potassium hydroxide solution (Solcera, medical device) versus placebo and investigator-blinded comparison with 3% diclofenac gel (Solaraze, medicinal product). It is performed in accordance with both the laws in force for clinical trials with medical devices and those with medicinal products.<\/li>\n<li>February 2024: Galderma Laboratorium GmbH- The objective of this non-interventional study (NIS) is to gain comprehensive insights into the practicability of ADL-PDT with Metvix&reg; in patients with actinic keratoses under real-world conditions.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover which therapies are expected to grab the Actinic Keratosis Market Share @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/actinic-keratosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Actinic Keratosis Market Outlook<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Actinic Keratosis Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Actinic keratosis (AK), also known as solar keratosis, is a common skin condition characterized by rough, scaly patches or lesions that develop on sun-exposed areas of the skin. These areas are typically affected by long-term exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Actinic Keratosis Epidemiology Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section of Actinic Keratosis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Actinic Keratosis Epidemiology trends @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/actinic-keratosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Actinic Keratosis Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Actinic Keratosis Drugs Market<\/strong><\/p>\n<p style=\"text-align: justify;\">The Actinic Keratosis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Actinic Keratosis signaling in Actinic Keratosis are likely to uncover new therapeutic targets and further expand treatment options for patients.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Actinic Keratosis Treatment Market Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\">The Actinic Keratosis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Actinic Keratosis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Actinic Keratosis treatment guidelines, visit @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/actinic-keratosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Actinic Keratosis Treatment Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Actinic Keratosis Market Outlook<\/strong><\/p>\n<p style=\"text-align: justify;\">The report&#8217;s outlook on the Actinic Keratosis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Actinic Keratosis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Actinic Keratosis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion\/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Actinic Keratosis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Actinic Keratosis Drugs Uptake<\/strong><\/p>\n<p style=\"text-align: justify;\">The drug chapter of the Actinic Keratosis report provides a comprehensive analysis of marketed and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Actinic Keratosis.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Major Actinic Keratosis Companies<\/strong><\/p>\n<p style=\"text-align: justify;\">Several companies working in the market include Novartis AG, GlaxoSmithKline plc, Almirall, LLC, LEO Pharma Inc., Cipher Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Biofrontera, Nestle SA, Bausch Health Companies Inc., Pierre Fabre Pharmaceuticals, Inc., and others<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the FDA-approved drugs for Actinic Keratosis @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/actinic-keratosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Drugs for Actinic Keratosis Treatment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Actinic Keratosis Market Research Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- 7MM<\/li>\n<li>Study Period- 20190-2032<\/li>\n<li>Actinic Keratosis Companies- Novartis AG, GlaxoSmithKline plc., Almirall, LLC, LEO Pharma Inc., Cipher Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Biofrontera, Nestle SA, Bausch Health Companies Inc., Pierre Fabre Pharmaceuticals, Inc., and others.<\/li>\n<li>Actinic Keratosis Pipeline Therapies- KX01 ointment 1%, Solaraze, Diclofenac Sodium Gel, Solaraze 3% Topical Gel, PEP005 Gel, and others.<\/li>\n<li>Actinic Keratosis Market Dynamics: Actinic Keratosis Market Drivers and Barriers<\/li>\n<li>Actinic Keratosis Market Access and Reimbursement, Unmet Needs and Future Perspectives<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about Actinic Keratosis Drugs in development @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/actinic-keratosis-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Actinic Keratosis Clinical Trials Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Actinic Keratosis<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Actinic Keratosis<\/p>\n<p style=\"text-align: justify;\">4. Actinic Keratosis: Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Actinic Keratosis: Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Actinic Keratosis Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Actinic Keratosis&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Actinic Keratosis Treatment<\/p>\n<p style=\"text-align: justify;\">11. Actinic Keratosis&nbsp;Marketed Products<\/p>\n<p style=\"text-align: justify;\">12. Actinic Keratosis&nbsp;Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">13. Actinic Keratosis: Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: Market Outlook<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Actinic Keratosis<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=actinic-keratosis-market-size-in-the-7mm-is-expected-to-grow-by-2032-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/medical-marijuana-market-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/medical-marijuana-market-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/medical-marijuana-market-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=actinic-keratosis-market-size-in-the-7mm-is-expected-to-grow-by-2032-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight&#8217;s &#8220;Actinic Keratosis Market Insights, Epidemiology, and Market Forecast-2032&#8221; report delivers an in-depth understanding of the Actinic Keratosis, historical and forecasted epidemiology as well as the Actinic Keratosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/actinic-keratosis-market-size-in-the-7mm-is-expected-to-grow-by-2032-delveinsight_694454.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-694454","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/694454","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=694454"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/694454\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=694454"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=694454"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=694454"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}